Drug Trial Radar · NCT06563999
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 1, 2024
Primary completion
Nov 1, 2027
Study completion Nov 1, 2029
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC). The aim of the umbrella study is to evaluate the efficacy of induction NGS-directed targeted therapies followed by surgery for stage III NSCLC patients whose tumor harbors a rare mutation.
Conditions
- Lung Cancer Stage III
- Mutation
Interventions
SunvozertinibDrug
300 mg orally once a day, 28 days as one cycle.
CrizotinibDrug
300 mg orally once a day, 28 days as one cycle.
PralsetinibDrug
400 mg orally once a day, 28 days as one cycle.
LarotrectinibDrug
100 mg orally twice daily, 28 days as one cycle.
SavolitinibDrug
600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle.
PyrotinibDrug
400 mg orally once a day, 28 days as one cycle.
Dabrafenib+TrametinibDrug
Dabrafenib 150 mg orally twice daily, 28 days as one cycle. Trametinib 150 mg orally twice daily, 28 days as one cycle.
GlecirasibDrug
800 mg daily orally, 28 days as one cycle.
EnsartinibDrug
225 mg daily orally, 28 days as one cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Resectability rateTime frame: Baseline to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.